Ligand-dependent platelet-derived growth factor receptor (PDGFR)-α activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors

Cancer Research

Volumn 69, Issue 9, 2009, Pages 3937-3946

  McDermott, Ultan ^a   Ames, Rachel Y ^a   Iafrate, A John ^a   Maheswaran, Shyamala ^a   Stubbs, Hannah ^a   Greninger, Patricia ^a   Mccutcheon, Kaitlin ^a   Milano, Randy ^a   Tam, Angela ^a   Lee, Diana Y ^a   Lucien, Laury ^a   Brannigan, Brian W ^a   Ulkus, Lindsey E ^a   Ma, Xiao Jun ^b   Erlander, Mark G ^b   Haber, Daniel A ^a   Sharma, Sreenath V ^a   Settleman, Jeffrey ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b AviaraDx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL LINE; CELL PROLIFERATION; CELL SCREENING; CHRONIC MYELOID LEUKEMIA; DNA SEQUENCE; DRUG ACTIVITY; DRUG SENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RHABDOMYOSARCOMA; RNA INTERFERENCE; SARCOMA CELL; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

ANTIBODIES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; INDOLES; LIGANDS; LUNG NEOPLASMS; LYMPHOKINES; PLATELET-DERIVED GROWTH FACTOR; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RHABDOMYOSARCOMA; RNA, SMALL INTERFERING;

EID: 65949104526     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4327     Document Type: Article

References (31)

1. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activityof SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors:determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon αin metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
3. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacyand safetyof sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib:a randomised controlled trial. Lancet 2006; 368: 1329-38.
4. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previouslytreated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 650-6.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
6. Sandler A, GrayR, Perry MC, et al. Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 2006; 355: 2542-50.
7. Andrae J, Gallini R, Betsholtz C. Role of plateletderived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276-312.
8. Valius M, Kazlauskas A. Phospholipase C-γ1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal. Cell 1993; 73: 321-34.
9. Ross R, Raines EW, Bowen-Pope DF. The biologyof platelet-derived growth factor. Cell 1986; 46: 155-69.
10. Gazit A, Igarashi H, Chiu IM, et al. Expression of the normal human sis/PDGF-2 coding sequence induces cellular transformation. Cell 1984; 39: 89-97.
11. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-9.
12. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors:frequency, spectrum and in vitro sensitivityto imatinib. J Clin Oncol 2005; 23: 5357-64.
13. Rikova K, Guo A, Zeng Q, et al. Global surveyof phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-203.
14. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma:PDGFRA and the RAS/MAPK pathwayas therapeutic targets for metastatic disease. Nat Genet 2001; 29: 143-52.
15. McDermott U, Sharma SV, Dowell L, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors byusing high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007; 104: 19936-41.
16. McDermott U, Iafrate AJ, GrayNS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008; 68: 3389-95.
17. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChip SNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 2004; 20: 1233-40.
18. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-10.
19. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created byfusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-14.
20. Smolen GA, Sordella R, Muir B, et al. Amplification of MET mayidentifya subset of cancers with extreme sensitivityto the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006; 103: 2316-21.
21. Brennan PJ, Kumagai T, Berezov A, Murali R, Greene MI. HER2/neu:mechanisms of dimerization/oligomerization. Oncogene 2000; 19: 6093-101.
22. Sulzbacher I, Traxler M, Mosberger I, Lang S, Chott A. Platelet-derived growth factor-AA and -αreceptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol 2000; 13: 632-7.
23. Guha A, Dashner K, Black PM, Wagner JA, Stiles CD. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 1995; 60: 168-73.
24. Adams GP, Weiner LM. Monoclonal antibodytherapy of cancer. Nat Biotechnol 2005; 23: 1147-57.
25. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442-9.
26. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-smallcell lung cancer. Nature 2007; 448: 561-6.
27. Patel KU, Szabo SS, Hernandez VS, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtuallyall dermatofibrosarcoma protuberans cases when investigated bynewlydeveloped multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008; 39: 184-93.
28. Adams SF, Hickson JA, Hutto JY, Montag AG, Lengyel E, Yamada SD. PDGFR-αas a potential therapeutic target in uterine sarcomas. Gynecol Oncol 2007; 104: 524-8.
29. Kubo T, Piperdi S, Rosenblum J, et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008; 112: 2119-29.
30. Zwerner JP, May WA. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing familytumors. Oncogene 2001; 20: 626-33.
31. Bond M, Bernstein ML, Pappo A, et al. A phase II studyof imatinib mesylate in children with refractoryor relapsed solid tumors:a Children's OncologyGroup study. Pediatr Blood Cancer 2008; 50: 254-8.